A circulating exosomal microRNA panel as a novel biomarker for monitoring post‐transplant renal graft function

Chen, Yi-Meng; Han, Xu; Sun, Yangyang; He, Xiaozhou; Xue, Dong

doi:10.1111/jcmm.15861

Cited by 23 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 More recently, it has been suggested that proteomic analysis of circulating EVs in kidney transplant recipients might discriminate grafts with poor outcomes, 45 whereas Chen et al identified an exosomal miRNA panel (miR-21-5p, miR-210-3p, and miR-4639-5p) as a potential biomarker of chronic allograft dysfunction. 46 Assessment of kidney allograft rejection. Immune monitoring of kidney transplants and development of noninvasive biomarkers of immune-mediated injury is an unmet need in kidney transplantation.…”

Section: Q8mentioning

confidence: 99%

Extracellular vesicles in kidney transplantation: a state-of-the-art review

Ashcroft

Leighton

Elliott

et al. 2022

Kidney International

View full text Add to dashboard Cite

Kidney transplantation is the optimal treatment for patients with kidney Q5 failure; however, early detection and timely treatment of graft injury remain a challenge. Precise and noninvasive techniques of graft assessment and innovative therapeutics are required to improve kidney transplantation outcomes. Extracellular vesicles (EVs) are lipid bilayer-delimited particles with unique biosignatures and immunomodulatory potential, functioning as intermediaries of cell signalling. Promising evidence exists for the potential of EVs to develop precision diagnostics of graft dysfunction, and prognostic biomarkers for clinician decision making. The inherent targeting characteristics of EVs and their low immunogenic and toxicity profiles combined with their potential as vehicles for drug delivery make them ideal targets for development of therapeutics to improve kidney transplant outcomes. In this review, we summarize the current evidence for EVs in kidney transplantation, discuss common methodological principles of EV isolation and characterization, explore upcoming innovative approaches in EV research, and discuss challenges and opportunities to enable translation of research findings into clinical practice.

show abstract

Section: Q8mentioning

confidence: 99%

Extracellular vesicles in kidney transplantation: a state-of-the-art review

Ashcroft

Leighton

Elliott

et al. 2022

Kidney International

View full text Add to dashboard Cite

show abstract

“…Based on the emerging data from other scientific fields, it is expected that exosomal miRNA profiling could be a non-invasive method to detect disease or a way to monitor progression or treatment efficacy. miRNA profiling has been employed in a small number of studies in heart [ 159 ] or kidney transplant recipients [ 169 , 171 , 174 , 175 ]. Proposed signatures included several miRNA species overall, while none recurred in different signatures.…”

Section: Liquid Biopsy With the Use Of Sev In Solid Organ And Tissue Transplantationmentioning

confidence: 99%

“…In another study analyzing urinary exosomes, three overexpressed urinary exo-miRs (miR-146b, miR-155, andmiR-200a) in kidney recipients were negatively correlated with TAC dose, while miR-200a was positively correlated with proteinuria [ 174 ]. Investigators were also able to identify significant changes in exosomal cargo corresponding with calcineurin inhibitors toxicity [ 173 ] or eGFR < 60 mL/min/1.73 m 2 [ 175 ]. Candidate biomarkers for different clinical conditions were summarized in Table 1 .…”

Section: Liquid Biopsy With the Use Of Sev In Solid Organ And Tissue Transplantationmentioning

confidence: 99%

Small Extracellular Vesicles in Transplant Rejection

Gołębiewska

Wardowska

Pietrowska

et al. 2021

Cells

View full text Add to dashboard Cite

Small extracellular vesicles (sEV), which are released to body fluids (e.g., serum, urine) by all types of human cells, may stimulate or inhibit the innate and adaptive immune response through multiple mechanisms. Exosomes or sEV have on their surface many key receptors of immune response, including major histocompatibility complex (MHC) components, identical to their cellular origin. They also exhibit an ability to carry antigen and target leukocytes either via interaction with cell surface receptors or intracellular delivery of inflammatory mediators, receptors, enzymes, mRNAs, and noncoding RNAs. By the transfer of donor MHC antigens to recipient antigen presenting cells sEV may also contribute to T cell allorecognition and alloresponse. Here, we review the influence of sEV on the development of rejection or tolerance in the setting of solid organ and tissue allotransplantation. We also summarize and discuss potential applications of plasma and urinary sEV as biomarkers in the context of transplantation. We focus on the attempts to use sEV as a noninvasive approach to detecting allograft rejection. Preliminary studies show that both sEV total levels and a set of specific molecules included in their cargo may be an evidence of ongoing allograft rejection.

show abstract

“…Many studies show a relationship between exosomal miRNA, which are endogenous NPs, and renal function. Chen et al [ 145 ] aimed to create a circulating exosomal miRNA panel for the non-invasive assessment of renal function after transplantation. The exosomal miRNA panel has advantages, such as non-invasive procedure, miRNA stability and low susceptibility to external factors, and sensitivity in distinguishing chronic graft dysfunction from normal function.…”

Section: Nanoparticles In Diagnosis and Treatment Of Kidney Diseasesmentioning

confidence: 99%

The Application of Nanoparticles in Diagnosis and Treatment of Kidney Diseases

Paluszkiewicz

Martuszewski

Zaręba

et al. 2021

IJMS

View full text Add to dashboard Cite

Nanomedicine is currently showing great promise for new methods of diagnosing and treating many diseases, particularly in kidney disease and transplantation. The unique properties of nanoparticles arise from the diversity of size effects, used to design targeted nanoparticles for specific cells or tissues, taking renal clearance and tubular secretion mechanisms into account. The design of surface particles on nanoparticles offers a wide range of possibilities, among which antibodies play an important role. Nanoparticles find applications in encapsulated drug delivery systems containing immunosuppressants and other drugs, in imaging, gene therapies and many other branches of medicine. They have the potential to revolutionize kidney transplantation by reducing and preventing ischemia–reperfusion injury, more efficiently delivering drugs to the graft site while avoiding systemic effects, accurately localizing and visualising the diseased site and enabling continuous monitoring of graft function. So far, there are known nanoparticles with no toxic effects on human tissue, although further studies are still needed to confirm their safety.

show abstract

A circulating exosomal microRNA panel as a novel biomarker for monitoring post‐transplant renal graft function

Cited by 23 publications

References 48 publications

Extracellular vesicles in kidney transplantation: a state-of-the-art review

Extracellular vesicles in kidney transplantation: a state-of-the-art review

Small Extracellular Vesicles in Transplant Rejection

The Application of Nanoparticles in Diagnosis and Treatment of Kidney Diseases

Contact Info

Product

Resources

About